<DOC>
	<DOCNO>NCT00006235</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine liposomal doxorubicin carboplatin treat patient recurrent ovarian , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Liposomal Doxorubicin Carboplatin Treating Patients With Recurrent Ovarian , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose doxorubicin HCl liposome ( Doxil ) combine carboplatin patient recurrent ovarian , fallopian tube , primary peritoneal cancer . II . Determine toxicity regimen patient . III . Determine rate response patient treat regimen . OUTLINE : This dose escalation , multicenter study doxorubicin HCl liposome ( Doxil ) . Patients receive Doxil IV 1 hour carboplatin IV day 1 . Treatment continue every 4 week minimum 6 course absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos Doxil maximum tolerate dose ( MTD ) determine . The MTD define high dose 0 1 6 patient experience dose limit toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter recurrence death . PROJECTED ACCRUAL : Approximately 24 patient accrue study 1 year .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent ovarian , tubal , peritoneal cancer platinum sensitive ( i.e. , 6 month last chemotherapy ) Maximum 1 prior chemotherapy regimen comprise 6 treatment first recurrence Must 1 follow epithelial subtypes : Serous adenocarcinoma Endometrioid adenocarcinoma Mucinous adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed epithelial carcinoma Transitional cell Malignant Brenner tumor Adenocarcinoma otherwise specify Measurable evaluable disease Greater 2 cm CT scan , measurable PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Granulocyte count least 1,500/mm3 Hepatic : Bilirubin normal SGOT , SGPT , GGT , alkaline phosphatase great 2.5 time upper limit normal No acute hepatitis Renal : Creatinine clearance great 50 mL/min Cardiovascular : LVEF normal MUGA No congestive heart failure No unstable angina No myocardial infarction within past 6 month Abnormal cardiac conduction ( e.g. , bundle branch block , heart block ) allow disease stable least 6 month Other : No septicemia significant infection No severe gastrointestinal bleeding No malignancy within past 5 year except nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior anthracycline therapy At least 3 week since prior chemotherapy ovarian , fallopian tube , peritoneal cancer recover Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : At least 3 week since prior surgery ovarian , fallopian tube , peritoneal cancer recover Other : No prior cancer therapy would preclude study therapy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>Brenner tumor</keyword>
</DOC>